Patent · US Active

Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC)

US9352028B2 · kind B2 · utility

24Cited by

1References

67Claims

0Family size

Assignee

CureVac AG · DE

Inventors

Marijke Barner · Stuttgart, DE
Jochen Probst · Wolfschlugen, DE
Thomas Lander · Königstein, DE
Ingmar Hoerr · Tübingen, DE

Key dates

Filing date	Jan 25, 2013
Grant date	May 31, 2016
Priority date	—
Expiry date	Oct 14, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/86
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising the active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.